Last reviewed · How we verify
TUM012
At a glance
| Generic name | TUM012 |
|---|---|
| Also known as | Ex-vivo infusion |
| Sponsor | iCoat Medical AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TUM012 CI brief — competitive landscape report
- TUM012 updates RSS · CI watch RSS
- iCoat Medical AB portfolio CI